These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9058588)

  • 21. Cholecystokinin-induced desensitization, receptor phosphorylation, and internalization in the CHP212 neuroblastoma cell line.
    Rao RV; Hadac EM; Roettger BF; Miller LJ
    J Neurochem; 1997 Jun; 68(6):2356-62. PubMed ID: 9166728
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biochemical and cell biological mechanisms of cholecystokinin receptor regulation.
    Miller LJ; Dong M; Harikumar KG; Lisenbee CS
    Curr Top Med Chem; 2007; 7(12):1166-72. PubMed ID: 17584138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impaired resensitization and recycling of the cholecystokinin receptor by co-expression of its second intracellular loop.
    Ding XQ; Rao RV; Kuntz SM; Holicky EL; Miller LJ
    Mol Pharmacol; 2000 Dec; 58(6):1424-33. PubMed ID: 11093782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential effects of modification of membrane cholesterol and sphingolipids on the conformation, function, and trafficking of the G protein-coupled cholecystokinin receptor.
    Harikumar KG; Puri V; Singh RD; Hanada K; Pagano RE; Miller LJ
    J Biol Chem; 2005 Jan; 280(3):2176-85. PubMed ID: 15537636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of cell surface expression of nonactivated cholecystokinin receptors using bivalent ligand-induced internalization.
    Harikumar KG; Akgün E; Portoghese PS; Miller LJ
    J Med Chem; 2010 Apr; 53(7):2836-42. PubMed ID: 20235611
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phosphorylation and desensitization of the pancreatic cholecystokinin-A receptor.
    Willems PH; Smeets RL; Bosch RR; De Pont JJ
    Digestion; 1997; 58 Suppl 2():75-80. PubMed ID: 9302495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Applications of fluorescence in the characterization of the ligand-binding domain and activation of the cholecystokinin receptor.
    Harikumar KG; Miller LJ
    Pharmacol Toxicol; 2002 Dec; 91(6):286-9. PubMed ID: 12688370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monitoring the state of cholecystokinin receptor oligomerization after ligand binding using decay of time-resolved fluorescence anisotropy.
    Harikumar KG; Miller LJ
    Ann N Y Acad Sci; 2008 Nov; 1144():21-7. PubMed ID: 19076359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ionic mechanisms underlying cholecystokinin action in rat brain.
    Boden P; Woodruff GN
    Ann N Y Acad Sci; 1994 Mar; 713():129-37. PubMed ID: 7910440
    [No Abstract]   [Full Text] [Related]  

  • 30. Cholecystokinin receptor antagonists: a review.
    Silverman MA; Greenberg RE; Bank S
    Am J Gastroenterol; 1987 Aug; 82(8):703-8. PubMed ID: 3300275
    [No Abstract]   [Full Text] [Related]  

  • 31. [The promiscuous receptor].
    Rehfeld JF
    Ugeskr Laeger; 1996 Dec; 158(51):7422. PubMed ID: 9012063
    [No Abstract]   [Full Text] [Related]  

  • 32. Nonpeptidic Z360-Analogs Tagged with Trivalent Radiometals as Anti-CCK
    Nock BA; Kanellopoulos P; Chepurny OG; Rouchota M; Loudos G; Holz GG; Krenning EP; Maina T
    Pharmaceutics; 2022 Mar; 14(3):. PubMed ID: 35336041
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [
    Mansi R; Plas P; Vauquelin G; Fani M
    Pharmaceuticals (Basel); 2021 Dec; 14(12):. PubMed ID: 34959665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [
    Kaloudi A; Kanellopoulos P; Radolf T; Chepurny OG; Rouchota M; Loudos G; Andreae F; Holz GG; Nock BA; Maina T
    Mol Pharm; 2020 Aug; 17(8):3116-3128. PubMed ID: 32568549
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of monoclonal antagonist antibodies on calcitonin gene-related peptide receptor function and trafficking.
    Manoukian R; Sun H; Miller S; Shi D; Chan B; Xu C
    J Headache Pain; 2019 Apr; 20(1):44. PubMed ID: 31039731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Teaching an Old Drug New Tricks: Agonism, Antagonism, and Biased Signaling of Pilocarpine through M3 Muscarinic Acetylcholine Receptor.
    Pronin AN; Wang Q; Slepak VZ
    Mol Pharmacol; 2017 Nov; 92(5):601-612. PubMed ID: 28893976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Target-Mediated Drug Disposition Pharmacokinetic-Pharmacodynamic Model of Bosentan and Endothelin-1.
    Volz AK; Krause A; Haefeli WE; Dingemanse J; Lehr T
    Clin Pharmacokinet; 2017 Dec; 56(12):1499-1511. PubMed ID: 28401480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor Targeting and Pharmacokinetics of a Near-Infrared Fluorescent-Labeled δ-Opioid Receptor Antagonist Agent, Dmt-Tic-Cy5.
    Huynh AS; Estrella V; Stark VE; Cohen AS; Chen T; Casagni TJ; Josan JS; Lloyd MC; Johnson J; Kim J; Hruby VJ; Vagner J; Morse DL
    Mol Pharm; 2016 Feb; 13(2):534-44. PubMed ID: 26713599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The mass action equation in pharmacology.
    Kenakin T
    Br J Clin Pharmacol; 2016 Jan; 81(1):41-51. PubMed ID: 26506455
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gaddum Memorial Lecture 2014: receptors as an evolving concept: from switches to biased microprocessors.
    Kenakin T
    Br J Pharmacol; 2015 Sep; 172(17):4238-53. PubMed ID: 26075971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.